title: Increased IL-10/IL-17 ratio is aggravated along with the prognosis of patients with chronic lymphocytic leukemia.
abstract: OBJECTIVE
  This study is to investigate the association between the Treg/Th17 cells and prognosis of chronic lymphocytic leukemia (CLL).
  
  
  METHODS
  Totally 50 CLL patients and 20 Health controls were included in this study. Regulatory T (Treg) cells and the cell subset secreting IL-17 (Th17) in peripheral blood were detected with flow cytometry. Serum levels of IL-10 and IL-17 were determined with ELISA, and expression of Foxp3 and RORγt was assessed with quantitative real-time PCR.
  
  
  RESULTS
  Treg and Th17 cell proportions in peripheral blood in the CLL patients were significantly higher than control. Serum levels of IL-10 and IL-17, and expression of Foxp3 and RORγt, were significantly increased in the CLL patients. Ratios of Treg/Th17 and IL-10/IL-17 were significantly elevated in the CLL patients. Compared with those before treatment, Treg/Th17 and IL-10/IL-17 ratios were declined in the CLL patients in remission. Compared with the non-remission group, Treg cells were significantly decreased, while Th17 cells were significantly increased, resulting in decreased Treg/Th17 ratio, in the remission group. Moreover, the serum IL-10 level was significantly decreased, while the serum IL-17 level was significantly increased, resulting in declined IL-10/IL-17 ratio, in the remission group. Correlation analysis showed that, Treg and Th17 cell counts were significantly associated with CD38 and ZAP-70 expression in the CLL patients. Moreover, the IL-10/IL-17 ratio was also significantly associated with CLL prognostic factors.
  
  
  CONCLUSIONS
  Altered Treg/Th17 and IL-10/IL-17 ratios in CLL would be aggravated along with the disease progression, which might be used as indicators for the disease prognosis.
authors: Center of Hematology, the First Affiliated Hospital of Xinjiang Medical University, Hematology Institute of Xinjiang Uygur Autonomous Region, Urumqi 830054, Xinjiang, China.
authors: Nannan
authors: N
authors: Pang
authors: Center of Hematology, the First Affiliated Hospital of Xinjiang Medical University, Hematology Institute of Xinjiang Uygur Autonomous Region, Urumqi 830054, Xinjiang, China.
authors: Rui
authors: R
authors: Zhang
authors: Center of Hematology, the First Affiliated Hospital of Xinjiang Medical University, Hematology Institute of Xinjiang Uygur Autonomous Region, Urumqi 830054, Xinjiang, China.
authors: Jinhua
authors: J
authors: Li
authors: Center of Hematology, the First Affiliated Hospital of Xinjiang Medical University, Hematology Institute of Xinjiang Uygur Autonomous Region, Urumqi 830054, Xinjiang, China.
authors: Zhenghao
authors: Z
authors: Zhang
authors: Center of Hematology, the First Affiliated Hospital of Xinjiang Medical University, Hematology Institute of Xinjiang Uygur Autonomous Region, Urumqi 830054, Xinjiang, China.
authors: Hailong
authors: H
authors: Yuan
authors: Center of Hematology, the First Affiliated Hospital of Xinjiang Medical University, Hematology Institute of Xinjiang Uygur Autonomous Region, Urumqi 830054, Xinjiang, China.
authors: Gang
authors: G
authors: Chen
authors: Center of Hematology, the First Affiliated Hospital of Xinjiang Medical University, Hematology Institute of Xinjiang Uygur Autonomous Region, Urumqi 830054, Xinjiang, China.
authors: Fang
authors: F
authors: Zhao
authors: Center of Hematology, the First Affiliated Hospital of Xinjiang Medical University, Hematology Institute of Xinjiang Uygur Autonomous Region, Urumqi 830054, Xinjiang, China.
authors: Lei
authors: L
authors: Wang
authors: Center of Hematology, the First Affiliated Hospital of Xinjiang Medical University, Hematology Institute of Xinjiang Uygur Autonomous Region, Urumqi 830054, Xinjiang, China.
authors: Haizhou
authors: H
authors: Cao
authors: Center of Hematology, the First Affiliated Hospital of Xinjiang Medical University, Hematology Institute of Xinjiang Uygur Autonomous Region, Urumqi 830054, Xinjiang, China. Electronic address: jhuaqu@163.com.
authors: Jianhua
authors: J
authors: Qu
authors: State Key Lab Incubation Base of Xinjiang Major Diseases Research, the First Affiliated Hospital of Xinjiang Medical University, Urumqi 830054, Xinjiang, China; Basic Medical College of Xinjiang Medical University, Urumqi, Xinjiang 830011, China. Electronic address: 1601379937@qq.com.
authors: Jianbing
authors: J
authors: Ding
mesh_terms: D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use; D002699:Chlorambucil / Q000627:therapeutic use; D003520:Cyclophosphamide / Q000627:therapeutic use; D005260:Female; D051858:Forkhead Transcription Factors / Q000235:genetics; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D016753:Interleukin-10 / Q000097:blood*; D020381:Interleukin-17 / Q000097:blood*; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000097:blood / Q000188:drug therapy / Q000276:immunology*; D008297:Male; D008875:Middle Aged; D057132:Nuclear Receptor Subfamily 1, Group F, Member 3 / Q000235:genetics; D011379:Prognosis; D000069283:Rituximab / Q000627:therapeutic use; D050378:T-Lymphocytes, Regulatory / Q000276:immunology*; D058504:Th17 Cells / Q000276:immunology*; D014740:Vidarabine / Q000031:analogs & derivatives / Q000627:therapeutic use
chemical_list: D000970:Antineoplastic Agents; C418974:FOXP3 protein, human; D051858:Forkhead Transcription Factors; C508609:IL10 protein, human; D007166:Immunosuppressive Agents; D020381:Interleukin-17; D057132:Nuclear Receptor Subfamily 1, Group F, Member 3; C539900:RORC protein, human; D016753:Interleukin-10; D002699:Chlorambucil; D000069283:Rituximab; D003520:Cyclophosphamide; D014740:Vidarabine; C024352:fludarabine
keywords: Chronic lymphocytic leukemia (CLL); IL-10; IL-17; Regulatory T (Treg) cells; Th17 cells